Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alcon Inc. stock logo
ALC
Alcon
$80.62
+1.3%
$82.61
$69.44
$88.23
$39.23B0.91816,311 shs521,595 shs
DexCom, Inc. stock logo
DXCM
DexCom
$131.52
+0.6%
$129.81
$74.75
$142.00
$50.39B1.22.41 million shs2.11 million shs
Lonza Group AG stock logo
LZAGY
Lonza Group
$55.69
+1.0%
$55.45
$34.19
$66.00
$41.07B0.97121,667 shs28,705 shs
ResMed Inc. stock logo
RMD
ResMed
$180.35
+0.8%
$186.14
$132.24
$243.52
$26.31B0.671.03 million shs1.12 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alcon Inc. stock logo
ALC
Alcon
+1.35%-0.58%-3.58%+4.13%+10.47%
DexCom, Inc. stock logo
DXCM
DexCom
+0.62%-2.26%-1.25%+3.46%+6.30%
Lonza Group AG stock logo
LZAGY
Lonza Group
+0.98%-4.07%-5.53%+29.48%-13.57%
ResMed Inc. stock logo
RMD
ResMed
+0.84%-2.56%-6.07%+3.07%-20.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alcon Inc. stock logo
ALC
Alcon
2.6885 of 5 stars
3.32.00.80.01.30.82.5
DexCom, Inc. stock logo
DXCM
DexCom
4.3864 of 5 stars
1.54.00.04.73.22.53.1
Lonza Group AG stock logo
LZAGY
Lonza Group
0.9081 of 5 stars
0.03.00.80.02.50.01.9
ResMed Inc. stock logo
RMD
ResMed
4.8356 of 5 stars
3.41.04.24.52.61.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alcon Inc. stock logo
ALC
Alcon
2.64
Moderate Buy$91.2213.15% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.407.51% Upside
Lonza Group AG stock logo
LZAGY
Lonza Group
2.75
Moderate BuyN/AN/A
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$199.2010.45% Upside

Current Analyst Ratings

Latest LZAGY, DXCM, RMD, and ALC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Alcon Inc. stock logo
ALC
Alcon
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00 ➝ $95.00
4/10/2024
Alcon Inc. stock logo
ALC
Alcon
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$100.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
4/3/2024
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$148.00 ➝ $161.00
4/1/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$215.00 ➝ $224.00
3/27/2024
ResMed Inc. stock logo
RMD
ResMed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$215.00
3/14/2024
Alcon Inc. stock logo
ALC
Alcon
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Perform
3/13/2024
Alcon Inc. stock logo
ALC
Alcon
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00
3/12/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$165.00
3/4/2024
Alcon Inc. stock logo
ALC
Alcon
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $100.00
3/1/2024
Alcon Inc. stock logo
ALC
Alcon
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$92.00 ➝ $100.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alcon Inc. stock logo
ALC
Alcon
$9.46B4.20$5.31 per share15.17$41.83 per share1.93
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B14.00$2.08 per share63.17$5.35 per share24.58
Lonza Group AG stock logo
LZAGY
Lonza Group
$7.48B5.55$2.09 per share26.62$14.23 per share3.91
ResMed Inc. stock logo
RMD
ResMed
$4.22B6.28$7.88 per share22.90$28.11 per share6.42

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alcon Inc. stock logo
ALC
Alcon
$974M$1.9641.1323.232.0410.30%6.75%4.63%5/14/2024 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.31100.4058.982.2514.95%28.31%9.74%4/25/2024 (Confirmed)
Lonza Group AG stock logo
LZAGY
Lonza Group
$728.49MN/A0.0032.76N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.0529.8121.782.1919.77%23.86%14.78%4/25/2024 (Confirmed)

Latest LZAGY, DXCM, RMD, and ALC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024N/A
DexCom, Inc. stock logo
DXCM
DexCom
$0.27N/A-$0.27N/AN/AN/A  
4/25/2024N/A
ResMed Inc. stock logo
RMD
ResMed
$1.93N/A-$1.93N/AN/AN/A  
2/27/2024Q4 2023
Alcon Inc. stock logo
ALC
Alcon
$0.68$0.70+$0.02$0.54$2.34 billion$2.33 billion  
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
1/24/2024Q2 24
ResMed Inc. stock logo
RMD
ResMed
$1.81$1.88+$0.07$2.34$1.15 billion$1.16 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alcon Inc. stock logo
ALC
Alcon
N/AN/AN/AN/A4 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Lonza Group AG stock logo
LZAGY
Lonza Group
$0.090.16%N/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.921.06%+5.66%31.74%12 Years

Latest LZAGY, DXCM, RMD, and ALC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/24/2024
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.481.12%2/7/20242/8/20243/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alcon Inc. stock logo
ALC
Alcon
0.22
2.28
1.34
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
Lonza Group AG stock logo
LZAGY
Lonza Group
0.27
1.77
1.20
ResMed Inc. stock logo
RMD
ResMed
0.27
3.11
1.89

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alcon Inc. stock logo
ALC
Alcon
53.86%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Lonza Group AG stock logo
LZAGY
Lonza Group
0.04%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Alcon Inc. stock logo
ALC
Alcon
N/A
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
Lonza Group AG stock logo
LZAGY
Lonza Group
0.07%
ResMed Inc. stock logo
RMD
ResMed
1.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alcon Inc. stock logo
ALC
Alcon
25,000493.10 millionN/AOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600385.52 million383.93 millionOptionable
Lonza Group AG stock logo
LZAGY
Lonza Group
17,494744.69 million744.17 millionNot Optionable
ResMed Inc. stock logo
RMD
ResMed
10,140147.09 million145.31 millionOptionable

LZAGY, DXCM, RMD, and ALC Headlines

SourceHeadline
ResMed (RMD) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesResMed (RMD) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
zacks.com - April 22 at 10:21 AM
Ardevora Asset Management LLP Decreases Holdings in ResMed Inc. (NYSE:RMD)Ardevora Asset Management LLP Decreases Holdings in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 21 at 8:53 PM
ResMed Inc. (NYSE:RMD) Shares Purchased by Zurcher Kantonalbank Zurich CantonalbankResMed Inc. (NYSE:RMD) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank
marketbeat.com - April 20 at 6:35 AM
Reviewing ResMed (NYSE:RMD) and Orthofix Medical (NASDAQ:OFIX)Reviewing ResMed (NYSE:RMD) and Orthofix Medical (NASDAQ:OFIX)
americanbankingnews.com - April 20 at 2:36 AM
ResMed Inc. (NYSE:RMD) Shares Sold by Everence Capital Management Inc.ResMed Inc. (NYSE:RMD) Shares Sold by Everence Capital Management Inc.
marketbeat.com - April 19 at 6:43 AM
Analysts remain high on ResMed despite potential sleep apnea benefits from GLP-1sAnalysts remain high on ResMed despite potential sleep apnea benefits from GLP-1s
massdevice.com - April 18 at 1:12 PM
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Weeks ReleaseResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com - April 18 at 11:08 AM
ResMed Inc. (NYSE:RMD) Stake Raised by Mackenzie Financial CorpResMed Inc. (NYSE:RMD) Stake Raised by Mackenzie Financial Corp
marketbeat.com - April 18 at 6:31 AM
ResMed (RMD) Set to Announce Earnings on ThursdayResMed (RMD) Set to Announce Earnings on Thursday
americanbankingnews.com - April 18 at 1:58 AM
ResMed caught between two narratives: Bearish sleep apnea data and bullish analystsResMed caught between two narratives: Bearish sleep apnea data and bullish analysts
marketindex.com.au - April 18 at 1:33 AM
Tandem Investment Advisors Inc. Has $64.58 Million Stake in ResMed Inc. (NYSE:RMD)Tandem Investment Advisors Inc. Has $64.58 Million Stake in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 17 at 7:32 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
ResMed (NYSE:RMD) Sees Strong Trading VolumeResMed (NYSE:RMD) Sees Strong Trading Volume
marketbeat.com - April 17 at 4:53 PM
ResMed Unusual Options Activity For April 17ResMed Unusual Options Activity For April 17
benzinga.com - April 17 at 10:32 AM
Eli Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Test; ResMed DivesEli Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Test; ResMed Dives
investors.com - April 17 at 8:57 AM
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow downNeedham sees BSX, CNMD, RMD beating Street, despite medtech slow down
msn.com - April 14 at 6:59 PM
ResMed Inc. (NYSE:RMD) Shares Purchased by Mirae Asset Global Investments Co. Ltd.ResMed Inc. (NYSE:RMD) Shares Purchased by Mirae Asset Global Investments Co. Ltd.
marketbeat.com - April 14 at 5:19 AM
Vaughan David Investments LLC IL Purchases New Holdings in ResMed Inc. (NYSE:RMD)Vaughan David Investments LLC IL Purchases New Holdings in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 12 at 8:51 PM
Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in MarchShort interest in S&P 500 health stocks rises, Moderna among most shorted companies in March
msn.com - April 12 at 2:09 PM
ResMed Inc. Forecasted to Post Q1 2025 Earnings of $1.94 Per Share (NYSE:RMD)ResMed Inc. Forecasted to Post Q1 2025 Earnings of $1.94 Per Share (NYSE:RMD)
marketbeat.com - April 11 at 7:42 AM
Hendershot Investments Inc. Acquires Shares of 44,068 ResMed Inc. (NYSE:RMD)Hendershot Investments Inc. Acquires Shares of 44,068 ResMed Inc. (NYSE:RMD)
marketbeat.com - April 10 at 7:55 PM
Q3 2024 EPS Estimates for ResMed Inc. Lifted by Analyst (NYSE:RMD)Q3 2024 EPS Estimates for ResMed Inc. Lifted by Analyst (NYSE:RMD)
marketbeat.com - April 10 at 8:28 AM
Nisa Investment Advisors LLC Has $11.50 Million Position in ResMed Inc. (NYSE:RMD)Nisa Investment Advisors LLC Has $11.50 Million Position in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 9 at 6:38 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Alcon logo

Alcon

NYSE:ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Lonza Group logo

Lonza Group

OTCMKTS:LZAGY
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.